Busy days at Novartis: Licensing deal with Array for oncology drugs; major quarterly profit rise; buying up more generics with Oriel purchase; oral MS drug Gilenia draws closer to review; however, bad timing on Tekturna.
Nexavar and tailored treatments for lung cancer – The study found that Nexavar prevented lung-cancer from progressing in 61 percent of patients with KRAS mutations. The research, presented yesterday at the meeting of the American Association for Cancer Research in Washington, was designed to show how gene testing of tumors can improve treatment when drugs are matched with biomarkers that predict their success…more
Evista and tamoxifen guarding against breast cancer, but with some differences – The latest results from a landmark, long-running study find that both tamoxifen and raloxifene help prevent breast cancer in postmenopausal women, although some differences are starting to emerge between the two drugs. Raloxifene (Evista), originally an osteoporosis drug, was less effective at preventing invasive breast cancer and more effective against noninvasive breast cancer than tamoxifen. But raloxifene compensated by having fewer side effects and a lower likelihood of causing uterine cancer than its older cousin. Both drugs work by interfering with the ability of estrogen to fuel tumor growth…more
Social Media consulting – Listening/monitoring. Facebook pages. Strategy. Community-building. The Impactiviti Partner Network is your resource if you’re looking to move intelligently into social media. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Feeling blue? Good – here’s 10 Amazing Blue Animals for you…
JUST FOR FUN
Bring TIM to shorten those drawn-out meetings!
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board